Oxidative stress is thought to play a key role in the development of intestinal damage in inflammatory bowel disease (IBD), because of its primary involvement in intestinal cells' aberrant immune and inflammatory responses to dietary antigens and to the commensal bacteria. During the active disease phase, activated leukocytes generate not only a wide spectrum of pro-inflammatory cytokines, but also excess oxidative reactions, which markedly alter the redox equilibrium within the gut mucosa, and maintain inflammation by inducing redox-sensitive signaling pathways and transcription factors. Moreover, several inflammatory molecules generate further oxidation products, leading to a self-sustaining and auto-amplifying vicious circle, which eventually impairs the gut barrier. The current treatment of IBD consists of long-term conventional anti-inflammatory therapy and often leads to drug refractoriness or intolerance, limiting patients' quality of life. Immune modulators or anti-tumor necrosis factor α antibodies have recently been used, but all carry the risk of significant side effects and a poor treatment response. Recent developments in molecular medicine point to the possibility of treating the oxidative stress associated with IBD, by designing a proper supplementation of specific lipids to induce local production of anti-inflammatory derivatives, as well as by developing biological therapies that target selective molecules (i.e., nuclear factor-κB, NADPH oxidase, prohibitins, or inflammasomes) involved in redox signaling. The clinical significance of oxidative stress in IBD is now becoming clear, and may soon lead to important new therapeutic options to lessen intestinal damage in this disease. Antioxid. Redox Signal. 19, 1711–1747.
AndresenL, JorgensenVL, PernerA, HansenA, Eugen-OlsenJ, Rask-MadsenJ. Activation of nuclear factor kappaB in colonic mucosa from patients with collagenous and ulcerative colitis. Gut, 54:503–509. 2005.
8.
ArditeE, SansM, PanésJ, RomeroFJ, PiquéJM, Fernández-ChecaJC. Replenishment of glutathione levels improves mucosal function in experimental acute colitis. Lab Invest, 80:735–744. 2000.
9.
ArielA, ChiangN, AritaM, PetasisNA, SerhanCN. Aspirin-triggered lipoxin A4 and B4 analogs block extracellular signal-regulated kinase-dependent TNF-alpha secretion from human T cells. J Immunol, 170:6266–6272. 2003.
10.
AritaM, YoshidaM, HongS, TjonahenE, GlickmanJN, PetasisNA, BlumbergRS, SerhanCN. Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6 trinitrobenzene sulfonic acid-induced colitis. Proc Natl Acad Sci U S A, 102:7671–7676. 2005.
AsehnouneK, StrassheimD, MitraS, KimJY, AbrahamE. Involvement of reactive oxygen species in Toll-like receptor 4-dependent activation of NF-kappa B. J Immunol, 172:2522–2529. 2004.
13.
Balkis BudinS, OthmanF, LouisSR, Abu BakarM, RadziM, OsmanK, DasS, MohamedJ. Effect of alpha lipoic acid on oxidative stress and vascular wall of diabetic rats. Rom J Morphol Embryol, 50:23–30. 2009.
14.
BananA, ChoudharyS, ZhangY, FieldsJZ, anf KeshavarzianA. Oxidant-induced intestinal barrier disruption and its prevention by growth factors in a human colonic cell line: role of the microtubule cytoskeleton. Free Radic Biol Med, 28:727–738. 2000.
15.
BaregamianN, SongJ, BaileyCE, PapaconstantinouJ, EversBM, ChungDH. Tumor necrosis factor-alpha and apoptosis signal-regulating kinase 1 control reactive oxygen species release, mitochondrial autophagy, and c-Jun N-terminal kinase/p38 phosphorylation during necrotizing enterocolitis. Oxid Med Cell Longev, 2:297–306. 2009.
16.
BarksbyHE, LeaSR, PreshawPM, TaylorJJ. The expanding family of interleukin-1 cytokines and their role in destructive inflammatory disorders. Clin Exp Immunol, 149:217–225. 2007.
17.
BarrettJC, HansoulS, NicolaeDL, ChoJH, DuerrRH, RiouxJD, BrantSR, SilverbergMS, TaylorKD, BarmadaMM, BittonA, DassopoulosT, DattaLW, GreenT, GriffithsAM, KistnerEO, MurthaMT, RegueiroMD, RotterJI, SchummLP, SteinhartAH, TarganSR, XavierRJ. NIDDK IBD Genetics Consortium. LibioulleC, SandorC, LathropM, BelaicheJ, DewitO, GutI, HeathS, LaukensD, MniM, RutgeertsP, Van GossumA, ZelenikaD, FranchimontD, HugotJP, de VosM, VermeireS, LouisE. the Belgian-French IBD Consortium, the Wellcome Trust Case Control Consortium. CardonLR, AndersonCA, DrummondH, NimmoE, AhmadT, PrescottNJ, OnnieCM, FisherSA, MarchiniJ, GhoriJ, BumpsteadS, GwilliamR, TremellingM, DeloukasP, MansfieldJ, JewellD, SatsangiJ, MathewCG, ParkesM, GeorgesM, DalyMJ. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet, 40:955–962. 2008.
18.
BaudV, KarinM. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol, 11:372–377. 2001.
19.
BauerC, DuewellP, MayerC, LehrHA, FitzgeraldKA, DauerM, TschoppJ, EndresS, LatzE, SchnurrM. Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome. Gut, 59:1192–1199. 2010.
20.
BegueB, VerdierJ, Rieux-LaucatF, GouletO, MoraliA, CanioniD, HugotJP, DaussyC, VerkarreV, PigneurB, FischerA, KleinC, Cerf-BensussanN, RuemmeleFM. Defective IL10 signaling defining a subgroup of patients with inflammatory bowel disease. Am J Gastroenterol, 106:1544–1555. 2011.
21.
BeltránB, NosP, DasíF, IborraM, BastidaG, MartínezM, O'ConnorJE, SáezG, MoretI, PonceJ. Mitochondrial dysfunction, persistent oxidative damage, and catalase inhibition in immune cells of naïve and treated Crohn's disease. Inflamm Bowel Dis, 16:76–86. 2010.
BernsteinCN, FriedM, KrabshuisJH, CohenH, EliakimR, FedailS, GearryR, GohKL, HamidS, KhanAG, LeMairAW, MalfertheinerP, OuyangQ, ReyJF, SoodA, SteinwurzF, ThomsenOO, ThomsonA, WatermeyerG. World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010. Inflamm Bowel Dis, 16:112–124. 2010.
24.
BiasiF, AstegianoM, MainaM, LeonarduzziG, PoliG. Polyphenol supplementation as a complementary medicinal approach to treating inflammatory bowel disease. Curr Med Chem, 18:4851–4865. 2011.
25.
BiasiF, MasciaC, AstegianoM, ChiarpottoE, NanoM, VizioB, LeonarduzziG, PoliG. Pro-oxidant and proapoptotic effects of cholesterol oxidation products on human colonic epithelial cells: a potential mechanism of inflammatory bowel disease progression. Free Radic Biol Med, 47:1731–1741. 2009.
26.
BiasiF, TessitoreL, ZanettiD, CutrinJC, ZingaroB, ChiarpottoE, ZarkovicN, ServiddioG, PoliG. Associated changes of lipid peroxidation and transforminggrowth factor beta1 levels in human colon cancer during tumour progression. Gut, 50:361–367. 2002.
27.
BiasiF, VizioB, MasciaC, GaiaE, ZarkovicN, ChiarpottoE, LeonarduzziG, PoliG. c-Jun N-terminal kinase upregulation as a key event in the proapoptotic interaction between transforming growth factor-beta1 and 4-hydroxynonenal in colon mucosa. Free Radic Biol Med, 41:443–454. 2006.
BochkovVN, PhilippovaM, OskolkovaO, KadlA, FurnkranzA, KarabegE, AfonyushkinT, GruberF, BreussJ, MinchenkoA, MechtcheriakovaD, HohensinnerP, RychliK, WojtaJ, ResinkT, ErneP, BinderBR, LeitingerN. Oxidized phospholipids stimulate angiogenesis via autocrine mechanisms, implicating a novel role for lipid oxidation in the evolution of atherosclerotic lesions. Circ Res, 99:900–908. 2006.
30.
BrownAJ, JessupW. Oxysterols: sources, cellular storage and metabolism, and new insights into their roles in cholesterol homeostasis. Mol Aspects Med, 30:111–122. 2009.
31.
BrownSJ, GianniD, BokochG, MercerBA, HodderP, RosenHR. Probe report for NOX1 inhibitors. Probe Reports from the NIH Molecular Libraries Program [Internet]Bethesda (MD): National Center for Biotechnology Information (US), 2010Bookshelf ID: NBK47342PMID:21433358.
32.
BruewerM, LuegeringA, KucharzikT, ParkosCA, MadaraJL, HopkinsAM, NusratA. Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms. J Immunol, 171:6164–6172. 2003.
33.
BurkeJP, MulsowJJ, O'KeaneC, DochertyNG, WatsonRW, O'ConnellPR. Fibrogenesis in Crohn's disease. Am J Gastroenterol, 102:439–448. 2007.
34.
BurrinDG, StollB. Emerging aspects of gut sulfur amino acid metabolism. Curr Opin Clin Nutr Metab Care, 10:63–68. 2007.
35.
CalderPC. Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology?Br J Clin Pharmacol, 75:645–662. 2012.
36.
CaoW, FiocchiC, PricoloVE. Production of IL-1beta, hydrogen peroxide, and nitric oxide by colonic mucosa decreases sigmoid smooth muscle contractility in ulcerative colitis. Am J Physiol Cell Physiol, 289:C1408–C1416. 2005.
37.
CarrollIM, AndrusJM, Bruno-BárcenaJM, KlaenhammerTR, HassanHM, ThreadgillDS. Anti-inflammatory properties of Lactobacillus gasseri expressing manganese superoxide dismutase using the interleukin 10-deficient mouse model of colitis. Am J Physiol Gastrointest Liver Physiol, 293:G729–G738. 2007.
38.
ChaparroM, BurgueñoP, IglesiasE, PanésJ, MuñozF, BastidaG, CastroL, JiménezC, MendozaJL, Barreiro-de AcostaM, SenentSG, GomollónF, CalvetX, García-PlanellaE, GómezM, HernándezV, HinojosaJ, MañosaM, NyssenOP, GisbertJP. Infliximab salvage therapy after failure of ciclosporin in corticosteroid-refractory ulcerative colitis: a multicentre study. Aliment Pharmacol Ther, 35:275–283. 2012.
39.
Chiva-BlanchG, Urpi-SardaM, LlorachR, Rotches-RibaltaM, GuillénM, CasasR, ArranzS, Valderas-MartinezP, PortolesO, CorellaD, TinahonesF, Lamuela-RaventosRM, Andres-LacuevaC, EstruchR. Differential effects of polyphenols and alcohol of red wine on the expression of adhesion molecules and inflammatory cytokines related to atherosclerosis: a randomized clinical trial. Am J Clin Nutr, 95:326–334. 2012.
40.
ChoiYJ, SeelbachMJ, PuH, EumSY, ChenL, ZhangB, HennigB, ToborekM. Polychlorinated biphenyls disrupt intestinal integrity via NADPH oxidase-induced alterations of tight junction protein expression. Environ Health Perspect, 118:976–981. 2010.
41.
ChouchanaL, NarjozC, BeauneP, LoriotMA, RoblinX. Review article: benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease. Aliment Pharmacol Ther, 35:15–36. 2012.
42.
CircuML, AwTY. Redox biology of the intestine. Free Radic Res, 45:1245–1266. 2011.
43.
CleversH. At the crossroads of inflammation and cancer. Cell, 118:671–674. 2004.
44.
CollingwoodS, WitheringtonJ. Therapeutic approaches towards the treatment of gastroinstestinal disorders. Drug News Perspect, 20:139–144. 2007.
45.
ColombelJF, SandbornWJ, ReinischW, MantzarisGJ, KornbluthA, RachmilewitzD, LichtigerS, D'HaensG, DiamondRH, BroussardDL, TangKL, van der WoudeCJ, RutgeertsP. SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med, 362:1383–1395. 2010.
46.
CoombesJL, SiddiquiKR, Arancibia-CárcamoCV, HallJ, SunCM, BelkaidY, PowrieF. A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. J Exp Med, 204:1757–1764. 2007.
47.
Cordero RuizP, Castro MárquezC, Méndez RufiánV, Castro LariaL, Caunedo ÁlvarezA, Romero VázquezJ, Herrerías GutiérrezJM. Efficacy of adalimumab in patients with Crohn's disease and failure to infliximab therapy: a clinical series. Rev Esp Enferm Dig, 103:294–298. 2011.
48.
CorletoVD, PagniniC, MargagnoniG, GuagnozziD, TorreMS, MartorelliM, LatianoA, AnneseV, CaprilliR, Delle FaveG. IL-1beta-511 and IL-1RN*2 polymorphisms in inflammatory bowel disease: an Italian population study and meta-analysis of European studies. Dig Liver Dis, 42:179–184. 2010.
49.
CosnesJ, Gower-RousseauC, SeksikP, CortotA. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology, 140:1785–1794. 2011.
50.
CruzCM, RinnaA, FormanHJ, VenturaAL, PersechiniPM, OjciusDM. ATP activates a reactive oxygen species-dependent oxidative stress response and secretion of proinflammatory cytokines in macrophages. J Biol Chem, 282:2871–2879. 2007.
51.
DamianiCR, BenettonCA, StoffelC, BardiniKC, CardosoVH, Di GiuntaG, PinhoRA, Dal-PizzolF, StreckEL. Oxidative stress and metabolism in animal model of colitis induced by dextran sulfate sodium. J Gastroenterol Hepatol, 22:1846–1851. 2007.
52.
DaneseS, FiorinoG, ReinischW. Review article: causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF-α therapy. Aliment Pharmacol Ther, 34:1–10. 2011.
53.
DaneseS, MantovaniA. Inflammatory bowel disease and intestinal cancer: a paradigm of the Yin-Yang interplay between inflammation and cancer. Oncogene, 29:3313–3323. 2010.
54.
DaneseS, SansM, FiocchiC. The CD40/CD40L costimulatory pathway in inflammatory bowel disease. Gut, 53:1035–1043. 2004.
55.
DanesiF, PhilpottM, HuebnerC, BordoniA, FergusonLR. Food-derived bioactives as potential regulators of the IL-12/IL-23 pathway implicated in inflammatory bowel diseases. Mutat Res, 690:139–144. 2010.
56.
De BacquerD, ClaysE, DelangheJ, De BackerG. Epidemiological evidence for an association between habitual tea consumption and markers of chronic inflammation. Atherosclerosis, 189:428–435. 2006.
57.
D'HaensGR, PanaccioneR, HigginsPD, VermeireS, GassullM, ChowersY, HanauerSB, HerfarthH, HommesDW, KammM, LöfbergR, QuaryA, SandsB, SoodA, WatermeyerG, LashnerB, LémannM, PlevyS, ReinischW, SchreiberS, SiegelC, TarganS, WatanabeM, FeaganB, SandbornWJ, ColombelJF, TravisS. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when tostart, when to stop, which drug to choose, and how to predict response?Am J Gastroenterol, 106:199–212. 2011.
58.
D'IncàR, CardinR, BenazzatoL, AngrimanI, MartinesD, SturnioloGC. Oxidative DNA damage in the mucosa of ulcerative colitis increases with disease duration and dysplasia. Inflamm Bowel Dis, 10:23–27. 2004.
59.
DincerY, ErzinY, HimmetogluS, GunesKN, BalK, AkcayT. Oxidative DNA damage and antioxidant activity in patients with inflammatory bowel disease. Dig Dis Sci, 52:1636–1641. 2007.
60.
DionneS, D'AgataID, HiscottJ, VanounouT, SeidmanEG. Colonic explant production of IL-1and its receptor antagonist is imbalanced in inflammatory bowel disease (IBD)Clin Exp Immunol, 112:435–442. 1998.
61.
DostertC, PétrilliV, Van BruggenR, SteeleC, MossmanBT, TschoppJ. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science, 320:674–677. 2008.
EnglerMB, EnglerMM. The emerging role of flavonoid-rich cocoa and chocolate in cardiovascular health and disease. Nutr Rev, 64:109–118. 2006.
64.
FarhadiA, KeshavarzianA, Van de KarLD, JakateS, DommA, ZhangL, ShaikhM, BananA, FieldsJZ. Heightened responses to stressors in patients with inflammatory bowel disease. Am J Gastroenterol, 100:1796–1804. 2005.
65.
FavaF, DaneseS. Intestinal microbiota in inflammatory bowel disease: friend of foe?World J Gastroenterol, 17:557–566. 2011.
66.
FeaginsLA, SouzaRF, SpechlerSJ. Carcinogenesis in IBD: potential targets for the prevention of colorectal cancer. Nat Rev Gastroenterol Hepatol, 6:297–305. 2009.
67.
FergusonLR. Chronic inflammation and mutagenesis. Mutat Res, 690:3–11. 2010.
68.
FernandoMM, StevensCR, WalshEC, De JagerPL, GoyetteP, PlengeRM, VyseTJ, RiouxJD. Defining the role of the MHC in autoimmunity: a review and pooled analysis. PLoS Genet, 4:e1000024. 2008.
69.
Fichtner-FeiglS, FussIJ, PreissJC, StroberW, KitaniA. Treatment of murine Th1- and Th2-mediated inflammatory bowel disease with NF-kappa B decoy oligonucleotides. J Clin Invest, 115:3057–3071. 2005.
70.
FilippiJ, Al-JaouniR, WirothJB, HébuterneX, SchneiderSM. Nutritional deficiencies in patients with Crohn's disease in remission. Inflamm Bowel Dis, 12:185–191. 2006.
71.
FiorucciS, WallaceJL, MencarelliA, DistruttiE, RizzoG, FarnetiS, MorelliA, TsengJL, SuramanyamB, GuilfordWJ, ParkinsonJF. A beta-oxidation-resistant lipoxin A4 analog treats hapten-induced colitis by attenuating inflammation and immune dysfunction. Proc Natl Acad Sci U S A, 101:15736–15741. 2004.
72.
FörstermannU, MünzelT. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation, 113:1708–1714. 2006.
73.
FragaCG, GalleanoM, VerstraetenSV, OteizaPI. Basic biochemical mechanisms behind the health benefits of polyphenols. Mol Aspects Med, 31:435–445. 2010.
74.
FranchiL, ParkJH, ShawMH, Marina-GarciaN, ChenG, KimYG, NúñezG. Intracellular NOD-like receptors in innate immunity, infection and disease. Cell Microbiol, 10:1–8. 2008.
75.
FranchimontD, VermeireS, El HousniH, PierikM, Van SteenK, GustotT, QuertinmontE, AbramowiczM, Van GossumA, DevièreJ, RutgeertsP. Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis. Gut, 53:987–992. 2004.
76.
FrankeA, BalschunT, KarlsenTH, SventoraityteJ, NikolausS, MayrG, DominguesFS, AlbrechtM, NothnagelM, EllinghausD, SinaC, OnnieCM, WeersmaRK, StokkersPC, WijmengaC, GazouliM, StrachanD, McArdleWL, VermeireS, RutgeertsP, RosenstielP, KrawczakM, VatnMH. the IBSEN study group. MathewCG, SchreiberS. Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat Genet, 40:1319–1323. 2008.
77.
GaratC, ArendWP. Intracellular IL-1Ra type 1 inhibits IL-1-induced IL-6 and IL-8 production in Caco-2 intestinal epithelial cells through inhibition of p38 mitogen-activated protein kinase and NF-kappaB pathways. Cytokine, 23:31–40. 2003.
78.
GarencC, JulienP, LevyE. Oxysterols in biological systems: the gastrointestinal tract, liver, vascular wall and central nervous system. Free Radic Res, 44:47–73. 2010.
79.
GarrettWS, LordGM, PunitS, Lugo-VillarinoG, MazmanianSK, ItoS, GlickmanJN, GlimcherLH. Communicable ulcerative colitis induced by T-bet deficiency in the innate immune system. Cell, 131:33–45. 2007.
80.
GelbmannCM, LeebSN, VoglD, MaendelM, HerfarthH, ScholmerichJ, FalkW, RoglerG. Inducible CD40 expression mediates NFkappaB activation and cytokine secretion in human colonic fibroblasts. Gut, 52:1448–1456. 2003.
81.
GewirtzAT, Collier-HyamsLS, YoungAN, KucharzikT, GuilfordWJ, ParkinsonJF, WilliamsIR, NeishAS, MadaraJL. Lipoxin a4 analogs attenuate induction of intestinal epithelial proinflammatory gene expression and reduce the severity of dextran sodium sulfate-induced colitis. J Immunol, 168:5260–5267. 2002.
HalliwellB. Oxygen and nitrogen are pro-carcinogens. Damage to DNA by reactive oxygen, chlorine and nitrogen species: measurement, mechanism and the effects of nutrition. Mutat Res, 443:37–52. 1999.
84.
HanaiH, IidaT, TakeuchiK, AraiH, AraiO, AbeJ, TanakaT, MaruyamaY, IkeyaK, SugimotoK, NakamuraT, NakamuraK, WatanabeF. Nutritional therapy versus 6-mercaptopurine as maintenance therapy in patients with Crohn's disease. Dig Liver Dis, 44:649–654. 2012.
HeidemannJ, DomschkeW, KucharzikT, MaaserC. Intestinal microvascular endothelium and innate immunity in inflammatory bowel disease: a second line of defense?Infect Immun, 74:5425–5432. 2006.
92.
HellerF, FlorianP, BojarskiC, RichterJ, ChristM, HillenbrandB, MankertzJ, GitterAH, BürgelN, FrommM, ZeitzM, FussI, StroberW, SchulzkeJD. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology, 129:550–564. 2005.
93.
HengstermannS, ValentiniL, SchaperL, BuningC, KoernickeT, MaritschneggM, BuhnerS, TillingerW, ReganoN, GuglielmiF, Winklhofer-RoobBM, LochsH. Altered status of antioxidant vitamins and fatty acids in patients with inactive inflammatory bowel disease. Clin Nutr, 27:571–578. 2008.
94.
HigashikuboA, TanakaN, NodaN, MaedaI, YagiK, MizoguchiT, NanriH. Increase in thioredoxin activity of intestinal epithelial cells mediated by oxidative stress. Biol Pharm Bull, 22:900–903. 1999.
95.
HirotaSA, NgJ, LuengA, KhajahM, ParharK, LiY, LamV, PotentierMS, NgK, BawaM, McCaffertyDM, RiouxKP, GhoshS, XavierRJ, ColganSP, TschoppJ, MuruveD, MacDonaldJA, BeckPL. NLRP3 inflammasome plays a key role in the regulation of intestinal homeostasis. Inflamm Bowel Dis, 17:1359–1372. 2011.
96.
HoltmannMH, NeurathMF. Anti-TNF strategies in stenosing and fistulizing Crohn's disease. Int J Colorectal Dis, 20:1–8. 2005.
97.
HsiehSY, ShihTC, YehCY, LinCJ, ChouYY, LeeYS. Comparative proteomic studies on the pathogenesis of human ulcerative colitis. Proteomics, 6:5322–5331. 2006.
98.
HuangJ, CanadienV, LamGY, SteinbergBE, DinauerMC, MagalhaesMA, GlogauerM, GrinsteinS, BrumellJH. Activation of antibacterial autophagy by NADPH oxidases. Proc Natl Acad Sci U S A, 106:6226–6231. 2009.
99.
HudertCA, WeylandtKH, LuY, WangJ, HongS, DignassA, SerhanCN, KangJX. Transgenic mice rich in endogenous omega-3 fatty acids are protected from colitis. Proc Natl Acad Sci U S A, 103:11276–11281. 2006.
100.
HussainSP, AmstadP, RajaK, AmbsS, NagashimaM, BennettWP, ShieldsPG, HamAJ, SwenbergJA, MarrogiAJ, HarrisCC. Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. Cancer Res, 60:3333–3337. 2000.
101.
IborraM, MoretI, RausellF, BastidaG, AguasM, CerrilloE, NosP, BeltránB. Role of oxidative stress and antioxidant enzymes in Crohn's disease. Biochem Soc Trans, 39:1102–1106. 2011.
IshiiY, ItohK, MorishimaY, KimuraT, KiwamotoT, IizukaT, HegabA, HosoyaT, NomuraA, SakamotoT, YamamotoM, SekizawaK. Transcription factor Nrf2 plays a pivotal role in protection against elastase induced pulmonary inflammation and emphysema. J Immunol, 175:6968–6975. 2005.
107.
JeongW, JungY, KimH, ParkSJ, RheeSG. Thioredoxin-related protein 14, a new member of the thioredoxin family with disulfide reductase activity: implication in the redox regulation of TNF-alpha signaling. Free Radic Biol Med, 47:1294–1303. 2009.
108.
JózsefL, ZoukiC, PetasisNA, SerhanCN, FilepJG. Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit peroxynitrite formation, NF-kappa B and AP-1 activation, and IL-8 gene expression in human leukocytes. Proc Natl Acad Sci U S A, 99:13266–13267. 2002.
109.
JungY, KimH, MinSH, RheeSG, JeongW. Dynein light chain LC8 negatively regulates NF-kappaB through the redox-dependent interaction with IkappaBalpha. J Biol Chem, 283:23863–23871. 2008.
110.
KaderHA, TchernevVT, SatyarajE, LejnineS, KotlerG, KingsmoreSF, PatelDD. Protein microarray analysis of disease activity in pediatric inflammatory bowel disease demonstrates elevated serum PLGF, IL-7, TGF-beta1, and IL-12p40 levels in Crohn's disease and ulcerative colitis patients in remission versus active disease. Am J Gastroenterol, 100:414–423. 2005.
111.
KannerJ. Dietary advanced lipid oxidation endproducts are risk factors to human health. Mol Nutr Food Res, 51:1094–1101. 2007.
112.
KaserA, ZeissigS, BlumbergRS. Genes and environment: how will our concepts on the pathophysiology of IBD develop in the future?Dig Dis, 28:395–405. 2010.
113.
KawanishiS, HirakuY, PinlaorS, MaN. Oxidative and nitrative DNA damage in animals and patients with inflammatory diseases in relation to inflammation-related carcinogenesis. Biol Chem, 387:365–372. 2006.
114.
KelsallB. Interleukin-10 in inflammatory bowel disease. N Engl J Med, 361:2091–2093. 2009.
115.
KeppO, GalluzziL, KroemerG. Mitochondrial control of the NLRP3 inflammasome. Nat Immunol, 12:199–200. 2011.
116.
KeshavarzianA, BananA, FarhadiA, KomanduriS, MutluE, ZhangY, FieldsJZ. Increases in free radicals and cytoskeletal protein oxidation and nitration in the colon of patients with inflammatory bowel disease. Gut, 52:720–728. 2003.
117.
KhanKJ, DubinskyMC, FordAC, UllmanTA, TalleyNJ, MoayyediP. Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol, 106:630–642. 2011.
118.
KhanMA, SteinerTS, ShamHP, BergstromKS, HuangJT, AssiK, SalhB, TaiIT, LiX, VallanceBA. The single IgG IL-1-related receptor controls TLR responses in differentiated human intestinal epithelial cells. J Immunol, 184:2305–2313. 2010.
119.
KhorTO, HuangMT, KwonKH, ChanJY, ReddyBS, KongAN. Nrf2-deficient mice have an increased susceptibility to dextran sulfate sodium-induced colitis. Cancer Res, 66:11580–11584. 2006.
120.
KhorTO, HuangM-T, PrawanA, LiuY, HaoX, YuS, CheungWKL, ChanJY, ReddyBS, YangCS, KongA-N. Increased susceptibility of Nrf2 knockout mice to colitis-associated colorectal cancer. Cancer Prev Res, 1:187–191. 2008.
121.
KimGS, JungJE, NarasimhanP, SakataH, ChanPH. Induction of thioredoxin-interacting protein is mediated by oxidative stress, calcium, and glucose after brain injury in mice. Neurobiol Dis, 46:440–449. 2012.
122.
KimJ, ChaY-N, SurhY-J. A protective role of nuclear factor-erythroid 2-related factor-2 (Nrf2) in inflammatory disorders. Mut Res, 690:12–23. 2010.
123.
KimSW, KimES, MoonCM, ParkJJ, KimTI, KimWH, CheonJH. Genetic polymorphisms of IL-23R and IL-17A and novel insights into their associations with inflammatory bowel disease. Gut, 60:1527–1536. 2011.
124.
KimYS, HoSB. Intestinal goblet cells and mucins in health and disease: recent insights and progress. Curr Gastroenterol Rep, 12:319–330. 2010.
125.
KimuraH, MukaidaM, KuwabaraK, ItoT, HashinoK, UchidaK, MatsumotoK, YoshidaK. 4-Hydroxynonenal modifies IgA in rat intestine after lipopolysaccharide injection. Free Radic Biol Med, 41:973–978. 2006.
126.
KjellevS. The trefoil factor family—small peptides with multiple functionalities. Cell Mol Life Sci, 66:1350–1369. 2009.
127.
KobayashiM, YamamotoM. Molecular mechanisms activating the Nrf2-Keap1 pathway of antioxidant gene regulation. Antioxid Redox Signal, 7:385–394. 2005.
128.
KoliosG, ValatasV, WardSG. Nitric oxide in inflammatory bowel disease: a universal messenger in an unsolved puzzle. Immunology, 113:427–437. 2004.
129.
KongX, ThimmulappaR, KombairajuP, BiswalS.NADPH oxidase-dependent reactive oxygen species mediate amplified TLR4 signaling and sepsis-induced mortality in Nrf2-deficient mice. J Immunol, 185:569–577. 2010.
130.
KoslowskiMJ, BeisnerJ, StangeEF, WehkampJ. Innate antimicrobial host defense in small intestinal Crohn's disease. Int J Med Microbiol, 300:34–40. 2010.
131.
KrieglsteinCF, AnthoniC, CerwinkaWH, StokesKY, RussellJ, GrishamMB, GrangerDN. Role of blood- and tissue-associated inducible nitric-oxide synthase in colonic inflammation. Am J Pathol, 170:490–496. 2007.
132.
KruidenierL, KuiperI, van DuijnW, MarklundSL, van HogezandRA, LamersCB, VerspagetHW. Differential mucosal expression of three superoxide dismutase isoforms in inflammatory bowel disease. J Pathol, 201:7–16. 2003.
133.
KruidenierL, KuiperI, Van DuijnW, Mieremet-OomsMA, van HogezandRA, LamersCB, VerspagetHW. Imbalanced secondary mucosal antioxidant response in inflammatory bowel disease. J Pathol, 201:17–27. 2003.
134.
KruidenierL, KuiperI, LamersCB, VerspagetHW. Intestinal oxidative damage in inflammatory bowel disease: semi-quantification, localization, and association with mucosal antioxidants. J Pathol, 201:28–36. 2003.
135.
KrupaLZ, KennedyHJ, JamiesonCP, FisherN, HartAR. The reasons for discontinuation of infliximab treatment in patients with Crohn's disease: a review of practice at NHS teaching hospital. ISRN Gastroenterol, 2011:672017. 2011.
136.
Krzystek-KorpackaM, NeubauerK, BerdowskaI, ZielinskiB, ParadowskiL, GamianA. Impaired erythrocyte antioxidant defense in active inflammatory bowel disease: impact of anemia and treatment. Inflamm Bowel Dis, 16:1467–1475. 2010.
KuiperHC, BrunoRS, TraberMG, StevensJF. Vitamin C supplementation lowers urinary levels of 4-hydroperoxy-2-nonenal metabolites in humans. Free Radic Biol Med, 50:848–853. 2011.
140.
KuwanoY, TominagaK, KawaharaT, SasakiH, TakeoK, NishidaK, MasudaK, KawaiT, Teshima-KondoS, RokutanK. Tumor necrosis factor alpha activates transcription of the NADPH oxidase organizer 1 (NOXO1) gene and upregulates superoxide production in colon epithelial cells. Free Radic Biol Med, 45:1642–1652. 2008.
141.
KwonKH, OhigashiH, MurakamiA. Dextran sulfate sodium enhances interleukin-1 beta release via activation of p38 MAPK and ERK1/2 pathways in murine peritoneal macrophages. Life Sci, 81:362–371. 2007.
142.
LandbergR, SunQ, RimmEB, CassidyA, ScalbertA, MantzorosCS, HuFB, van DamRM. Selected dietary flavonoids are associated with markers of inflammation and endothelial dysfunction in U.S. women. J Nutr, 141:618–625. 2011.
143.
LeachST, MessinaI, LembergDA, NovickD, RubensteinM, DayAS. Local and systemic interleukin-18 and interleukin-18-binding protein in children with inflammatory bowel disease. Inflamm Bowel Dis, 14:68–74. 2008.
144.
LeeIA, BaeEA, HyunYJ, KimDH. Dextran sulfate sodium and 2,4,6-trinitrobenzene sulfonic acid induce lipid peroxidation by the proliferation of intestinal gram-negative bacteria in mice. J Inflamm (Lond), 7:7. 2010.
145.
Legrand-PoelsS, KustermansG, BexF, KremmerE, KuferTA, PietteJ. Modulation of Nod2-dependent NF-kappaB signaling by the actin cytoskeleton. J Cell Sci, 120:1299–1310. 2007.
146.
LemaireS, LizardG, MonierS, MiguetC, GueldryS, VolotF, GambertP, NéelD. Different patterns of IL-1beta secretion, adhesion molecule expression and apoptosis induction in human endothelial cells treated with 7alpha-,7beta-hydroxycholesterol, or 7-ketocholesterol. FEBS Lett, 440:434–439. 1998.
147.
LeonarduzziG, GambaP, SotteroB, KadlA, RobbesynF, CalogeroRA, BiasiF, ChiarpottoE, LeitingerN, SevanianA, PoliG. Oxysterol-induced up-regulation of MCP-1 expression and synthesis in macrophage cells. Free Radic Biol Med, 39:1152–1161. 2005.
148.
LeonarduzziG, ScavazzaA, BiasiF, ChiarpottoE, CamandolaS, VogelS, DargelR, PoliG. The lipid peroxidation end product 4-hydroxy-2,3-nonenal up-regulates transforming growth factor beta1 expression in the macrophage lineage: a link between oxidative injury and fibrosclerosis. FASEB J, 11:851–857. 1997.
149.
LeonarduzziG, TestaG, SotteroB, GambaP, PoliG. Design and development of nanovehicle based delivery systems for preventive or therapeutic supplementation with flavonoids. Curr Med Chem, 17:74–95. 2010.
150.
LiH, LinX. Positive and negative signaling components involved in TNFalpha-induced NF-kappaB activation. Cytokine, 41:1–8. 2008.
151.
LiQ, SpencerNY, OakleyFD, BuettnerGR, EngelhardtJF. Endosomal Nox2 facilitates redox-dependent induction of NF-kappaB by TNF-alpha. Antioxid Redox Signal, 11:1249–1263. 2009.
LinPW, MyersLE, RayL, SongSC, NasrTR, BerardinelliAJ, KunduK, MurthyN, HansenJM, NeishAS. Lactobacillus rhamnosus blocks inflammatory signaling in vivo via reactive oxygen species generation. Free Radic Biol Med, 47:1205–1211. 2009.
154.
LipinskiS, TillA, SinaC, ArltA, GrasbergerH, SchreiberS, RosenstielP. DUOX2-derived reactive oxygen species are effectors of NOD2-mediated antibacterial responses. J Cell Sci, 122:3522–3530. 2009.
155.
LiuY, HulténLM, WiklundO. Macrophages isolated from human atherosclerotic plaques produce IL-8, and oxysterols may have a regulatory function for IL-8 production. Arterioscler Thromb Vasc Biol, 17:317–323. 1997.
156.
LiuZJ, YadavPK, SuJL, WangJS, FeiK. Potential role of Th17 cells in the pathogenesis of inflammatory bowel disease. World J Gastroenterol, 15:5784–5788. 2009.
157.
LizardG, LemaireS, MonierS, GueldryS, NéelD, GambertP. Induction of apoptosis and of interleukin-1beta secretion by 7beta-hydroxycholesterol and 7-ketocholesterol: partial inhibition by Bcl-2 overexpression. FEBS Lett, 419:276–280. 1997.
158.
LoguercioC, D'ArgenioG, Delle CaveM, CosenzaV, Della ValleN, MazzaccaG, Del Vecchio BlancoC. Glutathione supplementation improves oxidative damage in experimental colitis. Dig Liver Dis, 35:635–641. 2003.
159.
LooYM, GaleMJr.Immune signaling by RIG-I-like receptors. Immunity, 34:680–692. 2011.
160.
ManginoMJ, BrountsL, HarmsB, HeiseC. Lipoxin biosynthesis in inflammatory bowel disease. Prostaglandins Other Lipid Mediat, 79:84–92. 2006.
161.
MarcinkiewiczJ, CiszekM, BobekM, StrusM, HeczkoPB, KurnytaM, BiedrońR, ChmielarczykA. Differential inflammatory mediator response in vitro from murine macrophages to lactobacilli and pathogenic intestinal bacteria. Int J Exp Pathol, 88:155–164. 2007.
MasciaC, MainaM, ChiarpottoE, LeonarduzziG, PoliG, BiasiF. Proinflammatory effect of cholesterol and its oxidation products on CaCo-2 human enterocyte-like cells: effective protection by epigallocatechin-3-gallate. Free Radic Biol Med, 49:2049–2057. 2010.
MeiraLB, BugniJM, GreenSL, LeeCW, PangB, BorenshteinD, RickmanBH, RogersAB, Moroski-ErkulCA, McFalineJL, SchauerDB, DedonPC, FoxJG, SamsonLD. DNA damage induced by chronic inflammation contributes to colon carcinogenesis in mice. J Clin Invest, 118:2516–2525. 2008.
167.
MerkwirthC, DargazanliS, TatsutaT, GeimerS, LöwerB, WunderlichFT, von Kleist-RetzowJC, WaismanA, WestermannB, LangerT. Prohibitins control cell proliferation and apoptosis by regulating OPA1-dependent cristae morphogenesis in mitochondria. Genes Dev, 22:476–488. 2008.
168.
Miralles-BarrachinaO, SavoyeG, Belmonte-ZalarL, HochainP, DucrottéP, HecketsweilerB, LereboursE, DéchelotteP. Low levels of glutathione in endoscopic biopsies of patients with Crohn's colitis: the role of malnutrition. Clin Nutr, 18:313–317. 1999.
169.
MiroliaeeAE, EsmailyH, Vaziri-BamiA, BaeeriM, ShahverdiAR, AbdollahiM. Amelioration of experimental colitis by a novel nanoselenium-silymarin mixture. Toxicol Mech Methods, 21:200–208. 2011.
170.
MishraS, MurphyLC, NyombaBL, MurphyLJ. Prohibitin: a potential target for new therapeutics. Trends Mol Med, 11:192–197. 2005.
171.
MoehleC, AckermannN, LangmannT, AslanidisC, KelA, Kel-MargoulisO, Schmitz-MadryA, ZahnA, StremmelW, SchmitzG. Aberrant intestinal expression and allelic variants of mucin genes associated with inflammatory bowel disease. J Mol Med (Berl), 84:1055–1066. 2006.
172.
MoiP, ChanK, AsunisI, CaoA, KanYW. Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region. Proc Natl Acad Sci U S A, 91:9926–9930. 1994.
173.
MonteleoneG, BoirivantM, PalloneF, MacDonaldTT. TGF-beta1 and Smad7 in the regulation of IBD. Mucosal Immunol, 1:S50–S53. 2008.
174.
MooreSF, MacKenzieAB. NADPH oxidase NOX2 mediates rapid cellular oxidation following ATP stimulation of endotoxin-primed macrophages. J Immunol, 183:3302–3308. 2009.
175.
MorrisonPJ, BallantyneSJ, KullbergMC. Interleukin-23 and T helper 17-type responses in intestinal inflammation: from cytokines to T-cell plasticity. Immunology, 133:397–408. 2011.
176.
MukherjeeA, MoroskySA, ShenL, WeberCR, TurnerJR, KimKS, WangT, CoyneCB. Retinoic acid-induced gene-1 (RIG-I) associates with the actin cytoskeleton via caspase activation and recruitment domain-dependent interactions. J Biol Chem, 284:6486–6494. 2009.
177.
NaftaliT, NovickD, GabayG, RubinsteinM, NovisB. Interleukin-18 and its binding protein in patients with inflammatory bowel disease during remission and exacerbation. Isr Med Assoc J, 9:504–508. 2007.
178.
NairJ, GansaugeF, BegerH, DolaraP, WindeG, BartschH. Increased etheno-DNA adducts in affected tissues of patients suffering from Crohn's disease, ulcerative colitis, and chronic pancreatitis. Antioxid Redox Signal, 8:1003–1010. 2006.
179.
NairMG, GuildKJ, DuY, ZaphC, YancopoulosGD, ValenzuelaDM, MurphyA, StevensS, KarowM, ArtisD. Goblet cell-derived resistin-like molecule beta augments CD4+ T cell production of IFN-gamma and infection-induced intestinal inflammation. J Immunol, 181:4709–4715. 2008.
NijtmansLG, ArtalSM, GrivellLA, CoatesPJ. The mitochondrial PHB complex: roles in mitochondrial respiratory complex assembly, ageing and degenerative disease. Cell Mol Life Sci, 59:143–155. 2002.
187.
NijtmansLG, de JongL, Artal SanzM, CoatesPJ, BerdenJA, BackJW, MuijsersAO, van der SpekH, GrivellLA. Prohibitins act as a membrane-bound chaperone for the stabilization of mitochondrial proteins. EMBO J, 19:2444–2451. 2000.
188.
NishikawaM, OshitaniN, MatsumotoT, NishigamiT, ArakawaT, InoueM. Accumulation of mitochondrial DNA mutation with colorectal carcinogenesis in ulcerative colitis. Br J Cancer, 93:331–337. 2005.
189.
NittiM, DomenicottiC, d'AbramoC, AsseretoS, CottalassoD, MelloniE, PoliG, BiasiF, MarinariUM, PronzatoMA. Activation of PKC-beta isoforms mediates HNE-induced MCP-1 release by macrophages. Biochem Biophys Res Commun, 294:547–552. 2002.
190.
NunesT, FiorinoG, DaneseS, SansM. Familial aggregation in inflammatory bowel disease: is it genes or environment?World J Gastroenterol, 17:2715–2722. 2011.
191.
OguraY, BonenDK, InoharaN, NicolaeDL, ChenFF, RamosR, BrittonH, MoranT, KaraliuskasR, DuerrRH, AchkarJP, BrantSR, BaylessTM, KirschnerBS, HanauerSB, NuñezG, ChoJH. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature, 411:603–606. 2001.
192.
OldenburgB, van Kats-RenaudH, KoningsbergerJC, van Berge HenegouwenGP, van AsbeckBS. Chemiluminescence in inflammatory bowel disease patients: a parameter of inflammatory activity. Clin Chim Acta, 310:151–156. 2001.
193.
OnizawaM, NagaishiT, KanaiT, NaganoK, OshimaS, NemotoY, YoshiokaA, TotsukaT, OkamotoR, NakamuraT, SakamotoN, TsuchiyaK, AokiK, OhyaK, YagitaH, WatanabeM. Signaling pathway via TNF-alpha/NF-kappaB in intestinal epithelial cells may be directly involved in colitis-associated carcinogenesis. Am J Physiol Gastrointest Liver Physiol, 296:G850–G859. 2009.
194.
OsburnWO, KarimB, DolanPM, LiuG, YamamotoM, HusoDL, KenslerTW. Increased colonic inflammatory injury and formation of aberrant crypt foci in Nrf2-deficient mice upon dextran sulfate treatment. Int J Cancer, 121:1883–1891. 2007.
195.
OshimaN, IshiharaS, RumiMA, AzizMM, MishimaY, KadotaC, MoriyamaI, IshimuraN, AmanoY, KinoshitaY. A20 is an early responding negative regulator of toll-like receptor 5 signalling in intestinal epithelial cells during inflammation. Clin Exp Immunol, 159:185–198. 2010.
196.
OsmanC, MerkwirthC, LangerT. Prohibitins and the functional compartmentalization of mitochondrial membranes. J Cell Sci, 122:3823–3830. 2009.
197.
Otaegui-ArrazolaA, Menéndez-CarreñoM, AnsorenaD, AstiasaránI. Oxysterols: a world to explore. Food Chem Toxicol, 48:3289–3303. 2010.
198.
PalloneF, MonteleoneG. Mechanisms of tissue damage in inflammatory bowel disease. Curr Opin Gastroenterol, 17:307–312. 2001.
199.
PanaccioneR, LoftusEVJr., BinionD, McHughK, AlamS, ChenN, GueretteB, MulaniP, ChaoJ. Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn's DiseaSe (ACCESS) trial. Can J Gastroenterol, 25:419–425. 2011.
200.
PasparakisM. IKK/NF-kappaB signaling in intestinal epithelial cells controls immune homeostasis in the gut. Mucosal Immunol, 1:S54–S57. 2008.
201.
PaulG, KhareV, GascheC. Inflamed gut mucosa: downstream of interleukin-10. Eur J Clin Invest, 42:95–109. 2012.
PoliG, SchaurRJ, SiemsWG, LeonarduzziG. 4-hydroxynonenal: a membrane lipid oxidation product of medicinal interest. Med Res Rev, 28:569–631. 2008.
204.
PorathD, RieggerC, DreweJ, SchwagerJ. Epigallocatechin-3-gallate impairs chemokine production in human colon epithelial cell lines. J Pharmacol Exp Ther, 315:1172–1180. 2005.
205.
PrasadS, MingrinoR, KaukinenK, HayesKL, PowellRM, MacDonaldTT, CollinsJE. Inflammatory processes have differential effects on claudins 2, 3 and 4 in colonic epithelial cells. Lab Invest, 85:1139–1162. 2005.
206.
PravdaJ. Radical induction theory of ulcerative colitis. World J Gastroenterol, 11:2371–2384. 2005.
207.
PreiserJC, Van GossumA, BerréJ, VincentJL, CarpentierY. Enteral feeding with a solution enriched with antioxidant vitamins A, C, and E enhances the resistance to oxidative stress. Crit Care Med, 28:3828–3832. 2000.
208.
QiuW, WuB, WangX, BuchananME, RegueiroMD, HartmanDJ, SchoenRE, YuJ, ZhangL. PUMA-mediated intestinal epithelial apoptosis contributes to ulcerative colitis in humans and mice. J Clin Invest, 121:1722–1732. 2011.
209.
RaddatzD, BockemühlM, RamadoriG. Quantitative measurement of cytokine mRNA in inflammatory bowel disease: relation to clinical and endoscopic activity and outcome. Eur J Gastroenterol Hepatol, 17:547–557. 2005.
210.
RamasundaraM, LeachST, LembergDA, DayAS. Defensins and inflammation: the role of defensins in inflammatory bowel disease. J Gastroenterol Hepatol, 24:202–208. 2009.
211.
RangamaniP, SirovichL. Survival and apoptotic pathways initiated by TNF-alpha: modeling and predictions. Biotechnol Bioeng, 97:1216–1229. 2007.
212.
RaviA, GargP, SitaramanSV. Matrix metalloproteinases in inflammatory bowel disease: boon or a bane?Inflamm Bowel Dis, 13:97–107. 2007.
213.
RezaieA, ParkerRD, AbdollahiM. Oxidative stress and pathogenesis of inflammatory bowel disease: an epiphenomenon or the cause?Dig Dis Sci, 52:2015–2021. 2007.
214.
RicciS, MacchiaG, RuggieroP, MaggiT, BossùP, XuL, MedagliniD, TagliabueA, HammarströmL, PozziG, BoraschiD. In vivo mucosal delivery of bioactive human interleukin 1 receptor antagonist produced by Streptococcus gordonii. BMC Biotechnol, 3:15. 2003.
215.
RoglerG, BrandK, VoglD, PageS, HofmeisterR, AndusT, KnuechelR, BaeuerlePA, ScholmerichJ, GrossV. Nuclear factor kappaB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology, 115:357–369. 1998.
216.
RokutanK, KawaharaT, KuwanoY, TominagaK, NishidaK, Teshima-KondoS. Nox enzymes and oxidative stress in the immunopathology of the gastrointestinal tract. Semin Immunopathol, 30:315–327. 2008.
217.
RomierB, SchneiderYJ, LarondelleY, DuringA. Dietary polyphenols can modulate the intestinal inflammatory response. Nutr Rev, 67:363–378. 2009.
218.
RyuJH, KimSH, LeeHY, BaiJY, NamYD, BaeJW, LeeDG, ShinSC, HaEM, LeeWJ. Innate immune homeostasis by the homeobox gene caudal and commensal-gut mutualism in Drosophila. Science, 319:777–782. 2008.
219.
SaitohT, FujitaN, JangMH, UematsuS, YangBG, SatohT, OmoriH, NodaT, YamamotoN, KomatsuM, TanakaK, KawaiT, TsujimuraT, TakeuchiO, YoshimoriT, AkiraS. Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1beta production. Nature, 456:264–268. 2008.
220.
SandsBE, BlankMA, DiamondRH, BarrettJP, Van DeventerSJ. Maintenance infliximab does not result in increased abscess development in fistulizing Crohn's disease: results from the ACCENT II study. Aliment Pharmacol Ther, 23:1127–1136. 2006.
ScharlauD, BorowickiA, HabermannN, HofmannT, KlenowS, MieneC, MunjalU, SteinK, GleiM. Mechanisms of primary cancer prevention by butyrate and other products formed during gut flora-mediated fermentation of dietary fibre. Mutat Res, 682:39–53. 2009.
223.
Scherz-ShouvalR, ShvetsE, FassE, ShorerH, GilL, ElazarZ. Reactive oxygen species are essential for autophagy and specifically regulate the activity of Atg4. EMBO J, 26:1749–1760. 2007.
SeidelinJB, NielsenOH. Continuous cytokine exposure of colonic epithelial cells induces DNA damage. Eur J Gastroenterol Hepatol, 17:363–369. 2005.
226.
SerhanCN. The resolution of inflammation: the devil in the flask and in the details. FASEB J, 25:1441–1448. 2011.
227.
SerhanCN, ClishCB, BrannonJ, ColganSP, ChiangN, GronertK. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J Exp Med, 192:1197–1204. 2000.
228.
SerhanCN, SavillJ. Resolution of inflammation: the beginning programs the end. Nat Immunol, 6:1191–1197. 2005.
229.
SethRB, SunL, EaCK, ChenZJ. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3. Cell, 122:669–682. 2005.
230.
SharmaA, QadriA. Vi polysaccharide of Salmonella typhi targets the prohibitin family of molecules in intestinal epithelial cells and suppresses early inflammatory responses. Proc Natl Acad Sci U S A, 101:17492–17497. 2004.
231.
ShengYH, HasnainSZ, FlorinTH, McGuckinMA. Mucins in inflammatory bowel diseases and colorectal cancer. J Gastroenterol Hepatol, 27:28–38. 2012.
ShimozawaM, NaitoY, ManabeH, UchiyamaK, KurodaM, KatadaK, YoshidaN, YoshikawaT. 7-Ketocholesterol enhances the expression of adhesion molecules on human aortic endothelial cells by increasing the production of reactive oxygen species. Redox Rep, 9:370–375. 2004.
234.
SidoB, HackV, HochlehnertA, LippsH, HerfarthC, DrögeW. Impairment of intestinal glutathione synthesis in patients with inflammatory bowel disease. Gut, 42:485–492. 1998.
235.
SiegmundB, FantuzziG, RiederF, Gamboni-RobertsonF, LehrHA, HartmannG, DinarelloCA, EndresS, EiglerA. Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-gamma and TNF-alpha production. Am J Physiol Regul Integr Comp Physiol, 281:R1264–R1273. 2001.
236.
SilverbergMS, ChoJH, RiouxJD, McGovernDP, WuJ, AnneseV, AchkarJP, GoyetteP, ScottR, XuW, BarmadaMM, KleiL, DalyMJ, AbrahamC, BaylessTM, BossaF, GriffithsAM, IppolitiAF, LahaieRG, LatianoA, ParéP, ProctorDD, RegueiroMD, SteinhartAH, TarganSR, SchummLP, KistnerEO, LeeAT, GregersenPK, RotterJI, BrantSR, TaylorKD, RoederK, DuerrRH. Ulcerative colitis-risk loci on chromosomes 1p36 and 12q15 found by genome-wide association study. Nat Genet, 41:216–220. 2009.
237.
SlavovaN, DrescherA, VisekrunaA, DullatS, KroesenAJ, RitzJP, BuhrHJ. NALP expression in Paneth cells provides a novel track in IBD signaling. Langenbecks Arch Surg, 395:351–357. 2010.
238.
SongYA, ParkYL, YoonSH, KimKY, ChoSB, LeeWS, ChungIJ, JooYE. Black tea polyphenol theaflavin suppresses LPS-induced ICAM-1 and VCAM-1 expression via blockage of NF-κB and JNK activation in intestinal epithelial cells. Inflamm Res, 60:493–500. 2011.
239.
SonoK, YamadaA, YoshimatsuY, TakadaN, SuzukiY. Factors associated with the loss of response to infliximab in patients with Crohn's disease. Cytokine, 59:410–416. 2012.
SotteroB, GambaP, GargiuloS, LeonarduzziG, PoliG. Cholesterol oxidation products and disease: an emerging topic of interest in medicinal chemistry. Curr Med Chem, 16:685–705. 2009.
242.
SripathiSR, HeW, AtkinsonCL, SmithJJ, LiuZ, ElledgeBM, JahngWJ. Mitochondrial-nuclear communication by prohibitin shuttling under oxidative stress. Biochemistry, 50:8342–8351. 2011.
243.
StablesMJ, GilroyDW. Old and new generation lipid mediators in acute inflammation and resolution. Prog Lipid Res, 50:35–51. 2011.
244.
SteglichG, NeupertW, LangerT. Prohibitins regulate membrane protein degradation by the m-AAA protease in mitochondria. Mol Cell Biol, 19:3435–3442. 1999.
245.
SungSC, KimK, LeeKA, ChoiKH, KimSM, SonYH, MoonYS, EoSK, RhimBY. 7-Ketocholesterol upregulates interleukin-6 via mechanisms that are distinct from those of tumor necrosis factor-alpha, in vascular smooth muscle cells. J Vasc Res, 46:36–44. 2009.
246.
SurhJ, LeeS, KwonH. 4-hydroxy-2-alkenals in polyunsaturated fatty acids-fortified infant formulas and other commercial food products. Food Addit Contam, 24:1209–1218. 2007.
247.
SuzukiK, SugimuraK, HasegawaK, YoshidaK, SuzukiA, IshizukaK, OhtsukaK, HonmaT, NarisawaR, AsakuraH. Activated platelets in ulcerative colitis enhance the production of reactive oxygen species by polymorphonuclear leukocytes. Scand J Gastroenterol, 36:1301–1306. 2001.
248.
SzantoI, Rubbia-BrandtL, KissP, StegerK, BanfiB, KovariE, HerrmannF, HadengueA, KrauseKH. Expression of NOX1, a superoxide-generating NADPH oxidase, in colon cancer and inflammatory bowel disease. J Pathol, 207:164–176. 2005.
249.
TaiEK, WuWK, WongHP, LamEK, YuL, ChoCH. A new role for cathelicidin in ulcerative colitis in mice. Exp Biol Med (Maywood), 232:799–808. 2007.
250.
TakagiS, UtsunomiyaK, KuriyamaS, YokoyamaH, TakahashiS, IwabuchiM, TakahashiH, TakahashiS, KinouchiY, HiwatashiN, FunayamaY, SasakiI, TsujiI, ShimosegawaT. Effectiveness of an ‘half elemental diet’ as maintenance therapy for Crohn's disease: a randomized-controlled trial. Aliment Pharmacol Ther, 24:1333–1340. 2006.
251.
TakahashiY, MasudaH, IshiiY, NishidaY, KobayashiM, AsaiS. Decreased expression of thioredoxin interacting protein mRNA in inflamed colonic mucosa in patients with ulcerative colitis. Oncol Rep, 18:531–535. 2007.
252.
TamakiH, NakamuraH, NishioA, NakaseH, UenoS, UzaN, KidoM, InoueS, MikamiS, AsadaM, KiriyaK, KitamuraH, OhashiS, FukuiT, KawasakiK, MatsuuraM, IshiiY, OkazakiK, YodoiJ, ChibaT. Human thioredoxin-1 ameliorates experimental murine colitis in association with suppressed macrophage inhibitory factor production. Gastroenterology, 131:1110–1121. 2006.
253.
TardieuD, JaegJP, CadetJ, EmbvaniE, CorpetDE, PetitC. Dextran sulfate enhances the level of an oxidative DNA damage biomarker, 8-oxo-7,8-dihydro-2'-deoxyguanosine, in rat colonic mucosa. Cancer Lett, 134:1–5. 1998.
254.
TardieuD, JaegJP, DelolyA, CorpetDE, CadetJ, PetitCR. The COX-2 inhibitor nimesulide suppresses superoxide and 8-hydroxy-deoxyguanosine formation, and stimulates apoptosis in mucosa during early colonic inflammation in rats. Carcinogenesis, 21:973–976. 2000.
255.
TarganSR, KarpLC. Defects in mucosal immunity leading to ulcerative colitis. Immunol Rev, 206:296–305. 2005.
256.
te VeldeAA, PronkI, de KortF, StokkersPCF. Glutathione peroxidase 2 and aquaporin 8 as new markers for colonic inflammation in experimental colitis and inflammatory bowel diseases: an important role for H2O2?Eur J Gastroenterol Hepatol, 20:555–560. 2008.
257.
TebbuttNC, GiraudAS, IngleseM, JenkinsB, WaringP, ClayFJ, MalkiS, AldermanBM, GrailD, HollandeF, HeathJK, ErnstM. Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STAT-mediated trefoil gene activation in gp130 mutant mice. Nat Med, 8:1089–1097. 2002.
258.
TengX, XuLF, ZhouP, SunHW, SunM. Effects of trefoil peptide 3 on expression of TNF-alpha, TLR4, and NF-kappaB in trinitrobenzene sulphonic acid induced colitis mice. Inflammation, 32:120–129. 2009.
259.
TheissAL, JenkinsAK, OkoroNI, KlapprothJM, MerlinD, SitaramanSV. Prohibitin inhibits tumor necrosis factor alpha-induced nuclear factor-kappa B nuclear translocation via the novel mechanism of decreasing importin alpha3 expression. Mol Biol Cell, 20:4412–4423. 2009.
260.
TheissAL, IdellRD, SrinivasanS, KlapprothJM, JonesDP, MerlinD, SitaramanSV. Prohibitin protects against oxidative stress in intestinal epithelial cells. FASEB J, 21:197–206. 2007.
261.
TheissAL, LarouiH, ObertoneTS, ChowdhuryI, ThompsonWE, MerlinD, SitaramanSV. Nanoparticle-based therapeutic delivery of prohibitin to the colonic epithelial cells ameliorates acute murine colitis. Inflamm Bowel Dis, 17:1163–1176. 2011.
TheissAL, SitaramanSV. The role and therapeutic potential of prohibitin in disease. Biochim Biophys Acta, 1813:1137–1143. 2011.
264.
TheissAL, Vijay-KumarM, ObertoneTS, JonesDP, HansenJM, GewirtzAT, MerlinD, SitaramanSV. Prohibitin is a novel regulator of antioxidant response that attenuates colonic inflammation in mice. Gastroenterology, 137:199–208. 2009.
265.
ThieleK, BierhausA, AutschbachF, HofmannM, StremmelW, ThieleH, ZieglerR, NawrothPP. Cell specific effects of glucocorticoid treatment on the NF-kappaBp65/IkappaBalpha system in patients with Crohn's disease. Gut, 45:693–704. 1999.
266.
ThimmulappaR, LeeH, RangasamyT, ReddyS, YamamotoM, KenslerT, BiswalS. Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis. J Clin Invest, 116:984–995. 2006.
267.
TongY, YamaguchiH, GiaimeE, BoyleS, KopanR, KelleherRJ3rd, ShenJ. Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice. Proc Natl Acad Sci U S A, 107:9879–9884. 2010.
268.
TorunerM, LoftusEVJr., HarmsenWS, ZinsmeisterAR, OrensteinR, SandbornWJ, ColombelJF, EganLJ. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology, 134:929–936. 2008.
269.
UllmanTA, ItzkowitzSH. Intestinal inflammation and cancer. Gastroenterology, 140:1807–1816. 2011.
270.
Van der SluisM, De KoningBA, De BruijnAC, VelcichA, MeijerinkJP, Van GoudoeverJB, BüllerHA, DekkerJ, Van SeuningenI, RenesIB, EinerhandAW. Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology, 131:117–129. 2006.
271.
Van LimbergenJ, RussellRK, NimmoER, SatsangiJ. The genetics of inflammatory bowel disease. Am J Gastroenterol, 102:2820–2831. 2007.
272.
VetranoS, RescignoM, CeraMR, CorrealeC, RumioC, DoniA, FantiniM, SturmA, BorroniE, RepiciA, LocatiM, MalesciA, DejanaE, DaneseS. Unique role of junctional adhesion molecule-a in maintaining mucosal homeostasis in inflammatory bowel disease. Gastroenterology, 135:173–184. 2008.
273.
VillaniAC, LemireM, FortinG, LouisE, SilverbergMS, ColletteC, BabaN, LibioulleC, BelaicheJ, BittonA, GaudetD, CohenA, LangelierD, FortinPR, WitherJE, SarfatiM, RutgeertsP, RiouxJD, VermeireS, HudsonTJ, FranchimontD. Common variants in the NLRP3 region contribute to Crohn's disease susceptibility. Nat Genet, 41:71–76. 2009.
274.
VisekrunaA, JoerisT, SeidelD, KroesenA, LoddenkemperC, ZeitzM, KaufmannSH, Schmidt-UllrichR, SteinhoffU. Proteasome-mediated degradation of IkappaBalpha and processing of p105 in Crohn disease and ulcerative colitis. J Clin Invest, 116:3195–3203. 2006.
VongL, FerrazJG, DuftonN, PanaccioneR, BeckPL, ShermanPM, PerrettiM, WallaceJL. Up-regulation of annexin-A1 and lipoxin a(4) in individuals with ulcerative colitis may promote mucosal homeostasis. PLoS One, 7:e39244. 2012.
277.
VoraP, YoudimA, ThomasLS, FukataM, TesfaySY, LukasekK, MichelsenKS, WadaA, HirayamaT, ArditiM, AbreuMT. Beta-defensin-2 expression is regulated by TLR signaling in intestinal epithelial cells. J Immunol, 173:5398–5405. 2004.
278.
VossE, WehkampJ, WehkampK, StangeEF, SchröderJM, HarderJ. NOD2/CARD15 mediates induction of the antimicrobial peptide human beta-defensin-2. J Biol Chem, 281:2005–2011. 2006.
279.
CromerWE, MathisJM, GrangerDN, ChaitanyaGV, AlexanderJS. Role of the endothelium in inflammatory bowel diseases. World J Gastroenterol, 17:578–593. 2011.
280.
WangK, ZhangH, KugathasanS, AnneseV, BradfieldJP, RussellRK, SleimanPM, ImielinskiM, GlessnerJ, HouC, WilsonDC, WaltersT, KimC, FrackeltonEC, LionettiP, BarabinoA, Van LimbergenJ, GutheryS, DensonL, PiccoliD, LiM, DubinskyM, SilverbergM, GriffithsA, GrantSF, SatsangiJ, BaldassanoR, HakonarsonH. Diverse genome-wide association studies associate the IL12/IL23 pathway with Crohn Disease. Am J Hum Genet, 84:399–405. 2009.
281.
WangY, BogenhagenDF. Human mitochondrial DNA nucleoids are linked to protein folding machinery and metabolic enzymes at the mitochondrial inner membrane. J Biol Chem, 281:25791–25802. 2006.
282.
WeberCK, LiptayS, WirthT, AdlerG, SchmidRM. Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta. Gastroenterology, 119:1209–1218. 2000.
283.
WehkampJ, SalzmanNH, PorterE, NudingS, WeichenthalM, PetrasRE, ShenB, SchaeffelerE, SchwabM, LinzmeierR, FeathersRW, ChuH, LimaHJr., FellermannK, GanzT, StangeEF, BevinsCL. Reduced Paneth cell alpha-defensins in ileal Crohn's disease. Proc Natl Acad Sci U S A, 102:18129–18134. 2005.
284.
WehkampJ, SchmidM, FellermannK, StangeEF. Defensin deficiency, intestinal microbes, and the clinical phenotypes of Crohn's disease. J Leukoc Biol, 77:460–465. 2005.
285.
WellsJM, RossiO, MeijerinkM, van BaarlenP. Epithelial crosstalk at the microbiota-mucosal interface. Proc Natl Acad Sci U S A, 108:4607–4614. 2011.
WeylandtKH, KangJX, WiedenmannB, BaumgartDC. Lipoxins and resolvins in inflammatory bowel disease. Inflamm Bowel Dis, 13:797–799. 2007.
288.
WullaertA, BonnetMC, PasparakisM. NF-κB in the regulation of epithelial homeostasis and inflammation. Cell Res, 21:146–158. 2011.
289.
XuY, JagannathC, LiuXD, SharafkhanehA, KolodziejskaKE, EissaNT. Toll-like receptor 4 is a sensor for autophagy associated with innate immunity. Immunity, 27:135–144. 2007.
290.
YamamotoM, SatoS, MoriK, HoshinoK, TakeuchiO, TakedaK, AkiraS. Cutting edge: a novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-beta promoter in the Toll-like receptor signaling. J Immunol, 169:6668–6672. 2002.
291.
Yamamoto-FurushoJK, Santiago-HernándezJJ, Pérez-HernándezN, Ramírez-FuentesS, FragosoJM, Vargas-AlarcónG. Interleukin 1 β (IL-1B) and IL-1 antagonist receptor (IL-1RN) gene polymorphisms are associated with the genetic susceptibility and steroid dependence in patients with ulcerative colitis. J Clin Gastroenterol, 45:531–535. 2011.
292.
YeD, MaTY. Cellular and molecular mechanisms that mediate basal and tumour necrosis factor-alpha-induced regulation of myosin light chain kinase gene activity. J Cell Mol Med, 12:1331–1346. 2008.
293.
YoshidaH, RussellJ, SenchenkovaEY, Almeida PaulaLD, GrangerDN. Interleukin-1beta mediates the extra-intestinal thrombosis associated with experimental colitis. Am J Pathol, 177:2774–2781. 2010.
294.
YouY, FuJJ, MengJ, HuangGD, LiuYH. Effect of N-acetylcysteine on the murine model of colitis induced by dextran sodium sulfate through up-regulating PON1 activity. Dig Dis Sci, 54:1643–1650. 2009.
295.
YuQT, SarutaM, AvanesyanA, FleshnerPR, BanhamAH, PapadakisKA. Expression and functional characterization of FOXP3+ CD4+ regulatory T cells in ulcerative colitis. Inflamm Bowel Dis, 13:191–199. 2007.
296.
ZakiMH, BoydKL, VogelP, KastanMB, LamkanfiM, KannegantiTD. The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis. Immunity, 32:379–391. 2010.
